Zevra Therapeutics (ZVRA) Revenue (2019 - 2026)

Zevra Therapeutics has reported Revenue for 8 years, with the latest figure at $36.2 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 77.44% year-over-year to $36.2 million; the trailing twelve-month figure through Mar 2026 stood at $122.3 million (up 201.95% YoY), and the FY2025 full-year result was $106.5 million, up 350.91% from the prior year.
• Revenue for Q1 2026 stood at $36.2 million, up from $34.2 million in the prior quarter.
• The five-year high for Revenue was $36.2 million in Q1 2026, with the low at $48000.0 in Q2 2022.
• Historically, Revenue has averaged $11.9 million across 5 years, with a median of $4.4 million in 2024.
• Annual changes were most pronounced in 2022 — Revenue sank 99.6% — and 2023, when it jumped 17545.83%.
• Zevra Therapeutics' Revenue stood at $2.2 million in 2022, then soared by 489.15% to $12.9 million in 2023, then dropped by 7.03% to $12.0 million in 2024, then soared by 184.47% to $34.2 million in 2025, then climbed by 5.94% to $36.2 million in 2026.
• The last three Revenue figures came in at $36.2 million (Q1 2026), $34.2 million (Q4 2025), and $26.1 million (Q3 2025), per Business Quant data.